Meeting
2011 Genitourinary Cancers Symposium
Phase II study of maintenance therapy with temsirolimus (TEM) after response to first-line docetaxel (TAX) chemotherapy in castration-resistant prostate cancer (CRPC).
Authors
Urban Emmenegger
Sunnybrook Odette Cancer Centre, University of Toronto
Urban Emmenegger , Scott Berry , Srikala Sridhar , Eric Winquist , Yoo-Joung Ko
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session B: Prostate Cancer
Track
Prostate Cancer
Sub Track
Prostate Cancer
Clinical Trial Registration Number
TEM Prostate
Citation
J Clin Oncol 29: 2011 (suppl 7; abstr 160)
Abstract #
160
Poster Bd #
A54
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Selection biases in the systematic collection of breast biobank specimens.
First Author: Yael Bar
Poster
2022 ASCO Annual Meeting
![CCTG PR21: A randomized phase II study of [<sup>177</sup>lu]lu-PSMA-617 verus docetaxel in patients with metastatic castration-resistant prostate cancer and PSMA-positive disease (NCT04663997).](https://d201v5jt9ylckg.cloudfront.net/288/14370/213296/213296_A1829_poster_pv.jpg)
CCTG PR21: A randomized phase II study of [177lu]lu-PSMA-617 verus docetaxel in patients with metastatic castration-resistant prostate cancer and PSMA-positive disease (NCT04663997).
First Author: Kim N. Chi
Poster
2016 ASCO Annual Meeting
A randomized, phase II study of repeated rhenium-188-HEDP (rhenium) combined with docetaxel versus docetaxel alone in castration resistant prostate cancer (CRPC) metastatic to bone: The Taxium II trial.
First Author: Joyce M. van Dodewaard-de Jong
Poster
2016 Genitourinary Cancers Symposium
A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod (TASQ) in patients (pts) with mCRPC responsive to or stabilized during first-line docetaxel chemotherapy.
First Author: Karim Fizazi